AUSTIN, Texas (PRWEB)
March 14, 2022

With rapid developments happening by the day in clinical research, the team at Benchmark Research have played a crucial role in studies over the last quarter decade. The experience and expertise Benchmark has earned is best reflected in the over 600+ vaccine trials and almost 100 device and diagnostic trials they have conducted.

Benchmark has worked closely with various leading organizations and has solidified continuous good relationships with the pharmaceutical companies, the CRO’s, and the FDA, because of their performance history for the highest standard of care and safety. This has resulted in a reputation that is recognized internationally by renowned firms such as ACRP, CISCRP, Greater Gift, PharmaVoice Magazine, Pharmatimes and pharmaceutical companies like Pfizer, Moderna, J&J, PPD and IQVIA.

The Benchmark team has conducted Phase 1, 2, and 3 COVID-19 studies amongst their other areas of expertise. These ongoing studies have seen the enrolment of over 5,000+ volunteers across eight sites in 45+ COVID-19 related trials. During the peak of COVID-19, Benchmark was placed in a highly public position, with the team keeping the general population informed of any developments that have been made.

“We are honored to be recognized as a finalist for the Excellence in Innovation Award. While we have achieved some incredible feats over the years, we cannot match how proud we are of our company for what we have achieved and the impact we made during the COVID-19 pandemic. Our staff at all levels have been involved in this effort and have come together in amazing ways, and our quality of work was amplified through these efforts during those unique and uncertain times. We are confident that Benchmark has played a meaningful role in the route to finding a safe and effective vaccine for COVID-19 and the trials that followed, for which we are immensely grateful for.” – Mark Lacy, Founder and CEO of Benchmark Research

Share article on social media or email: